ArticleAmerican journal of preventive medicine2025
Statin Use and Cardiovascular Risk in Young Adults in the United States.
Article in American journal of preventive medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Atorvastatin pre-exposure in hypercholesterolemia remedies 27HC mediated dendritic cell dysfunctions in triple-negative breast cancer.Molecular therapy. Oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionAtherosclerotic cardiovascular disease pathogenesis begins in early adulthood, yet guidance on statin use for primary prevention in young adults is limited.
methodsThis is a retrospective multicenter cohort study of adults aged 20-39 years receiving primary care within 87 U.S. health systems (2022-2023). The study included patients with at least 1 low-density lipoprotein cholesterol (LDL-C) measurement. The primary outcome was the measured the proportion of patients prescribed a statin within 1 month of LDL-C testing. The characteristics of those who were and were not prescribed statins were compared using standardized mean differences. Finally, the PREVENT 10- and 30-year ASCVD risk scores for the "average" patient (using the cohort mean values of risk score variables), a "lower-risk" patient, and a "higher-risk" patient were compared (using pooled values 1 SD below and above the mean, respectively). Analyses were conducted in 2024-2025.
resultsStatins were initiated in 3,309 of 775,162 patients. Those who received statins were more likely to be older, male, and have higher mean LDL-C, systolic blood pressure, HgA1c, and BMI (standardized mean differences >0.10). PREVENT 10-year risk scores were similar or higher among those prescribed statins compared to those not prescribed statins for the average (0.75% vs 0.76%), lower-risk (0.19% vs 0.35%), and higher-risk (8.87% vs 4.55%) groups.
conclusionsIn a multicenter cohort, 0.43% of young adults were prescribed a statin within 1 month of initial LDL-C measurement. The average patient would not have qualified for statin therapy based on their PREVENT risk percentile. Future studies should evaluate the cost effectiveness of statins for primary prevention in patients aged 20 to 39 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.